JP2008528466A5 - - Google Patents

Download PDF

Info

Publication number
JP2008528466A5
JP2008528466A5 JP2007551740A JP2007551740A JP2008528466A5 JP 2008528466 A5 JP2008528466 A5 JP 2008528466A5 JP 2007551740 A JP2007551740 A JP 2007551740A JP 2007551740 A JP2007551740 A JP 2007551740A JP 2008528466 A5 JP2008528466 A5 JP 2008528466A5
Authority
JP
Japan
Prior art keywords
cancer
compound according
disease
condition
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2007551740A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008528466A (ja
Filing date
Publication date
Priority claimed from GB0501480A external-priority patent/GB0501480D0/en
Priority claimed from GB0501748A external-priority patent/GB0501748D0/en
Application filed filed Critical
Priority claimed from PCT/GB2006/000193 external-priority patent/WO2006077416A1/en
Publication of JP2008528466A publication Critical patent/JP2008528466A/ja
Publication of JP2008528466A5 publication Critical patent/JP2008528466A5/ja
Withdrawn legal-status Critical Current

Links

JP2007551740A 2005-01-21 2006-01-20 Ｃｄｋおよびｇｓｋ阻害ピラゾール誘導体 Withdrawn JP2008528466A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US64621705P 2005-01-21 2005-01-21
GB0501480A GB0501480D0 (en) 2005-01-22 2005-01-22 Pharmaceutical compounds
GB0501748A GB0501748D0 (en) 2005-01-27 2005-01-27 Pharmaceutical compounds
US65133905P 2005-02-09 2005-02-09
PCT/GB2006/000193 WO2006077416A1 (en) 2005-01-21 2006-01-20 Pyrazole derivatives for the inhibition of cdk' s and gsk' s

Publications (2)

Publication Number Publication Date
JP2008528466A JP2008528466A (ja) 2008-07-31
JP2008528466A5 true JP2008528466A5 (https=) 2009-03-12

Family

ID=35967182

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2007551740A Withdrawn JP2008528466A (ja) 2005-01-21 2006-01-20 Ｃｄｋおよびｇｓｋ阻害ピラゾール誘導体
JP2007551739A Pending JP2008528465A (ja) 2005-01-21 2006-01-20 Ｃｄｋおよびｇｓｋの阻害のためのピラゾール誘導体
JP2007551742A Pending JP2008528467A (ja) 2005-01-21 2006-01-20 Ｃｄｋおよびｇｓｋの阻害のためのピラゾール誘導体

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2007551739A Pending JP2008528465A (ja) 2005-01-21 2006-01-20 Ｃｄｋおよびｇｓｋの阻害のためのピラゾール誘導体
JP2007551742A Pending JP2008528467A (ja) 2005-01-21 2006-01-20 Ｃｄｋおよびｇｓｋの阻害のためのピラゾール誘導体

Country Status (15)

Country Link
US (2) US20080306069A1 (https=)
EP (3) EP1853600A1 (https=)
JP (3) JP2008528466A (https=)
KR (3) KR20070098927A (https=)
AR (3) AR052559A1 (https=)
AU (3) AU2006207311A1 (https=)
BR (2) BRPI0606317A2 (https=)
CA (3) CA2593468A1 (https=)
IL (3) IL184499A0 (https=)
MA (3) MA29255B1 (https=)
MX (3) MX2007008784A (https=)
NO (3) NO20073956L (https=)
PE (3) PE20060876A1 (https=)
TN (3) TNSN07278A1 (https=)
WO (3) WO2006077419A1 (https=)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2256106T3 (pl) 2003-07-22 2015-08-31 Astex Therapeutics Ltd Związki 3,4-pochodne 1h-pirazolu i ich zastosowanie jako kinazy zależne od cyklin (cdk) i modulatory kinazy syntazy glikogenu-3 (gsk-3)
TW200533657A (en) 2004-02-17 2005-10-16 Esteve Labor Dr Substituted pyrazoline compounds, their preparation and use as medicaments
JP5475234B2 (ja) * 2005-01-21 2014-04-16 アステックス・セラピューティクス・リミテッド 医薬化合物
US8404718B2 (en) 2005-01-21 2013-03-26 Astex Therapeutics Limited Combinations of pyrazole kinase inhibitors
US20080139620A1 (en) * 2005-01-21 2008-06-12 Astex Therapeutics Limited Pyrazole Derivatives For The Inhibition Of Cdk's And Gsk's
AR052559A1 (es) * 2005-01-21 2007-03-21 Astex Therapeutics Ltd Derivados de pirazol para inhibir cdk's y gsk's
MX2007008781A (es) * 2005-01-21 2007-09-11 Astex Therapeutics Ltd Compuestos farmaceuticos.
KR20070107707A (ko) * 2005-01-21 2007-11-07 아스텍스 테라퓨틱스 리미티드 피라졸 키나제 억제제와 추가 항종양제의 조합물
AR054425A1 (es) 2005-01-21 2007-06-27 Astex Therapeutics Ltd Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico.
US20090036607A1 (en) * 2005-03-03 2009-02-05 Mitsubishi Rayon Co., Ltd. Polymer particle, resin composition containing same, and molded body
EP1743890A1 (en) 2005-07-15 2007-01-17 Laboratorios Del Dr. Esteve, S.A. 4,5-Dihydro-1H-pyrazole derivatives, their preparation and use as medicaments
EP1743892A1 (en) 2005-07-15 2007-01-17 Laboratorios del Dr. Esteve S.A. Substituted pyrazoline compounds, their preparation and use as medicaments
US7897589B2 (en) 2005-07-15 2011-03-01 Laboratorios Del Dr. Esteve, S.A. Substituted pyrazoline compounds, their preparation and use as medicaments
EP2027109A1 (en) * 2006-05-05 2009-02-25 Astex Therapeutics Limited 4- (2, 6-dichloro-benzoylamino) -1h-pyrazole-s-carboxylic acid (1-methanesulph0nyl-piperidin-4-yl) -amide for the treatment of cancer
WO2007129062A1 (en) * 2006-05-08 2007-11-15 Astex Therapeutics Limited Pharmaceutical combinations of diazole derivatives for cancer treatment
WO2008007122A2 (en) * 2006-07-14 2008-01-17 Astex Therapeutics Limited Combinations of pyrazole derivatives for the inhibition of cdks and gsk's
EP2049516A2 (en) * 2006-07-14 2009-04-22 Astex Therapeutics Limited Pharmaceutical compounds
WO2008009954A1 (en) * 2006-07-21 2008-01-24 Astex Therapeutics Limited Medical use of cyclin dependent kinases inhibitors
US20110172230A1 (en) * 2006-08-23 2011-07-14 Takahiro Ishii Urea compound or salt thereof
WO2008044041A1 (en) 2006-10-12 2008-04-17 Astex Therapeutics Limited Pharmaceutical combinations
AU2007316558A1 (en) * 2006-11-09 2008-05-15 Abbott Gmbh & Co. Kg Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor
FR2908409B1 (fr) * 2006-11-10 2009-01-09 Sanofi Aventis Sa Pyrazoles substituees,compositions les contenant,procede de fabrication et utilisation
FR2913018A1 (fr) * 2007-02-23 2008-08-29 Sanofi Aventis Sa Solution solide amorphe contenant un derive de pyrazole-3-carboxamide sous forme amorphe et des excipients stabilisateurs
EP2267459A1 (en) * 2009-06-25 2010-12-29 Universite Pierre Et Marie Curie - Paris VI Method for determining the susceptibility of a cell strain to drugs
WO2012148994A1 (en) * 2011-04-25 2012-11-01 Usher Iii Initiative Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome
DE102011106990B3 (de) * 2011-07-08 2013-01-03 Technische Universität Darmstadt Verbindungen als Glykogen Synthase Kinase 3 (GSK-3) Inhibitoren für die Behandlung von GSK-3-vermittelten Erkrankungen
BRPI1107312B1 (pt) 2011-11-25 2021-09-08 Universidade Federal De Santa Catarina Composto de acil-hidrazona
CA2860250C (en) * 2012-02-21 2020-11-10 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. 1h-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors
US20150099645A1 (en) * 2012-03-14 2015-04-09 Stephen Marx Means and methods for diagnostics and therapeutics of diseases
US9227976B2 (en) 2012-10-25 2016-01-05 Usher Iii Initiative, Inc. Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome
US8765762B2 (en) 2012-10-25 2014-07-01 Usher III, Initiative, Inc. Pyrazolopyridazines and methods for treating retinal-degerative diseases and hearing loss associated with usher syndrome
WO2014066835A1 (en) * 2012-10-25 2014-05-01 Usher Iii Initiative, Inc. Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome
US9409895B2 (en) 2012-12-19 2016-08-09 Novartis Ag Autotaxin inhibitors
HK1212348A1 (en) 2012-12-19 2016-06-10 Novartis Ag Autotaxin inhibitors
US9603804B2 (en) 2013-04-25 2017-03-28 Kyorin Pharmaceutical Co., Ltd. Solid pharmaceutical composition
WO2014179144A1 (en) * 2013-04-29 2014-11-06 E. I. Du Pont De Nemours And Company Fungicidal heterocyclic compounds
EP2980088A1 (en) 2014-07-28 2016-02-03 Bayer Pharma Aktiengesellschaft Amino-substituted isothiazoles
WO2015113927A1 (en) * 2014-01-29 2015-08-06 Bayer Pharma Aktiengesellschaft Amino-substituted isothiazoles
JP2017528460A (ja) * 2014-09-10 2017-09-28 エピザイム インコーポレイテッド 不可逆的ｓｍｙｄ阻害剤としてのイソオキサゾールカルボキサミド
AU2015371251B2 (en) 2014-12-23 2020-06-11 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
HK1246645A1 (zh) 2015-03-27 2018-09-14 达纳-法伯癌症研究所股份有限公司 细胞周期蛋白依赖性激酶的抑制剂
TWI730959B (zh) 2015-05-19 2021-06-21 英商葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之雜環醯胺
WO2019188200A1 (ja) 2018-03-27 2019-10-03 ダイキン工業株式会社 スルファミン酸リチウムの製造方法及び新規スルファミン酸リチウム
JP7161122B2 (ja) 2018-03-27 2022-10-26 ダイキン工業株式会社 電解液、電気化学デバイス、リチウムイオン二次電池及びモジュール
PL3761435T3 (pl) 2018-03-27 2023-02-06 Daikin Industries, Ltd. Roztwór elektrolitu, urządzenie elektrochemiczne, litowo-jonowa bateria akumulatorowa, moduł oraz związek
US12187701B2 (en) 2018-06-25 2025-01-07 Dana-Farber Cancer Institute, Inc. Taire family kinase inhibitors and uses thereof
JP7660063B2 (ja) 2018-12-28 2025-04-10 ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド サイクリン依存性キナーゼ７のインヒビターおよびそれらの使用
CN111848579B (zh) * 2019-04-26 2023-11-14 君实润佳(上海)医药科技有限公司 4-(2,6-二氯苯甲酰氨基)-n-(4-哌啶基)-1h-吡唑-3-甲酰胺的前药
IL299695A (en) 2020-07-09 2023-03-01 Usher Iii Initiative Inc Treatment of cancer, inflammatory diseases and autoimmune diseases
AU2022271290A1 (en) 2021-05-07 2023-11-23 Kymera Therapeutics, Inc. Cdk2 degraders and uses thereof
TW202320750A (zh) * 2021-10-25 2023-06-01 香港商優領醫藥科技(香港)有限公司 含四氫呋喃多環類衍生物、其藥學上可接受的鹽及其製備方法和應用
TW202337434A (zh) * 2022-02-11 2023-10-01 美商傳達治療有限公司 Ｃｄｋ抑制劑及其使用方法
WO2026024674A1 (en) 2024-07-22 2026-01-29 Genesis Therapeutics, Inc. Methods of treating skp2-associated cancers

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4282361A (en) * 1978-03-16 1981-08-04 Massachusetts Institute Of Technology Synthesis for 7-alkylamino-3-methylpyrazolo [4,3-d]pyrimidines
US5502068A (en) * 1995-01-31 1996-03-26 Synphar Laboratories, Inc. Cyclopropylpyrroloindole-oligopeptide anticancer agents
JP2000504014A (ja) * 1996-01-30 2000-04-04 メルク エンド カンパニー インコーポレーテッド ファルネシル―タンパク質転移酵素の阻害剤
US6020357A (en) * 1996-12-23 2000-02-01 Dupont Pharmaceuticals Company Nitrogen containing heteroaromatics as factor Xa inhibitors
US6632815B2 (en) * 1999-09-17 2003-10-14 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
US20040087798A1 (en) * 2000-03-14 2004-05-06 Akira Yamada Novel amide compounds
US6455559B1 (en) * 2001-07-19 2002-09-24 Pharmacia Italia S.P.A. Phenylacetamido-pyrazole derivatives, process for their preparation and their use as antitumor agents
JPWO2002074298A1 (ja) * 2001-03-21 2004-07-08 小野薬品工業株式会社 Ｉｌ−６産生阻害剤
GB0218625D0 (en) * 2002-08-10 2002-09-18 Astex Technology Ltd Pharmaceutical compounds
US7169797B2 (en) * 2003-02-14 2007-01-30 Abbott Laboratories Protein-tyrosine phosphatase inhibitors and uses thereof
US7320989B2 (en) * 2003-02-28 2008-01-22 Encysive Pharmaceuticals, Inc. Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists
TWI372050B (en) * 2003-07-03 2012-09-11 Astex Therapeutics Ltd (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
PL2256106T3 (pl) * 2003-07-22 2015-08-31 Astex Therapeutics Ltd Związki 3,4-pochodne 1h-pirazolu i ich zastosowanie jako kinazy zależne od cyklin (cdk) i modulatory kinazy syntazy glikogenu-3 (gsk-3)
US20080139620A1 (en) * 2005-01-21 2008-06-12 Astex Therapeutics Limited Pyrazole Derivatives For The Inhibition Of Cdk's And Gsk's
KR20070107707A (ko) * 2005-01-21 2007-11-07 아스텍스 테라퓨틱스 리미티드 피라졸 키나제 억제제와 추가 항종양제의 조합물
JP5475234B2 (ja) * 2005-01-21 2014-04-16 アステックス・セラピューティクス・リミテッド 医薬化合物
AR054425A1 (es) * 2005-01-21 2007-06-27 Astex Therapeutics Ltd Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico.
MX2007008781A (es) * 2005-01-21 2007-09-11 Astex Therapeutics Ltd Compuestos farmaceuticos.
AR052559A1 (es) * 2005-01-21 2007-03-21 Astex Therapeutics Ltd Derivados de pirazol para inhibir cdk's y gsk's

Similar Documents

Publication Publication Date Title
JP2008528466A5 (https=)
US9284298B2 (en) Pyrazolyl-pyrimidine derivatives as kinase inhibitors
JP6959248B2 (ja) 癌治療用の４，６−ジヒドロピロロ［３，４−ｃ］ピラゾール−５（１Ｈ）−カルボニトリル誘導体
EP2880025B1 (en) Substituted pyrroles active as kinases inhibitors
CN103635189B (zh) 用于治疗癌症的含有cdk4/6抑制剂和pi3k抑制剂的联合治疗
JP6708661B2 (ja) Ｕｓｐ３０阻害剤としての１−シアノ−ピロリジン化合物
EP1043998B1 (en) USE OF PYRAZOLO [3,4-b] PYRIDINE AS CYCLIN DEPENDANT KINASE INHIBITORS
JP5703212B2 (ja) キナーゼ阻害剤としてのピロロピリジン
JP2016527263A5 (https=)
CZ297907B6 (cs) Aminothiazolové deriváty a farmaceutické kompozice s jejich obsahem
KR20170061175A (ko) 키나제 억제제로서 유용한 인돌 카르복스아미드 화합물
CN103003280A (zh) 作为cdk4/6抑制剂的氘化吡咯并嘧啶化合物
JP2016525078A5 (https=)
JP2017537946A5 (https=)
JP2008505167A5 (https=)
WO2012143248A1 (en) Substituted pyrimidinyl-pyrroles active as kinase inhibitors
WO2017049462A1 (zh) 一类新型的flt3激酶抑制剂及其用途
Elagawany et al. Design, synthesis, and molecular modelling of pyridazinone and phthalazinone derivatives as protein kinases inhibitors
KR101129088B1 (ko) Ｎ-［6-(시스-2,6-디메틸모르폴린-4-일)피리딘-3-일］-2-메틸-4'-(트리플루오로메톡시)［1,1'-비페닐］-3-카르복스아미드의 염
JP2017531680A (ja) 三環式アトロプ異性体の化合物
CN115956070A (zh) 磺酰胺化合物
Traquandi et al. Identification of potent pyrazolo [4, 3-h] quinazoline-3-carboxamides as multi-cyclin-dependent kinase inhibitors
EP3372589B1 (en) Pyrimidine derivative
WO2002002550A1 (en) Novel pyrazinone derivatives
JP2014522836A (ja) 併用療法